Evidence Hub

Successful Management of Steroid‐Refractory Immune‐Related Pneumonitis With Mycophenolate Mofetil: A Case Report

H. Ota, Daichi Fujimoto, Y. Negi, T. Murata, Mayuko Tokuda, T. Higashiyama, A. Tada, Toshiyuki Minami et al.

Respirology Case Reports, 2025

3 citations

Abstract

Steroid‐refractory immune‐related pneumonitis is a clinical challenge with limited evidence‐based treatment strategies. Current guidelines recommend the use of immunosuppressants; however, the optimal type and dosage of these agents remain unclear. Herein, we report a case of steroid‐refractory immune‐related pneumonitis that was successfully treated with mycophenolate mofetil (MMF). The patient did not respond to high‐dose steroid therapy as initial treatment but showed significant improvement in both subjective symptoms and imaging findings after the additional administration of MMF. Subsequent tapering of the MMF dose led to worsening imaging findings, which improved upon re‐escalation of the MMF dose. This case highlights the potential efficacy of MMF for the treatment of steroid‐refractory immune‐related pneumonitis and provides valuable insights into the administration of MMF and its potential role in managing similar cases.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free